Statistical analysis plan for a pragmatic phase III randomised controlled trial examining behaviour change physiotherapy intervention to increase physical activity following hip and knee replacements: the PEP-TALK Trial by Ooms, Alexander et al.
1 
 
Statistical analysis plan for a pragmatic phase III randomised controlled trial examining behaviour 1 
change physiotherapy intervention to increase physical activity following hip and knee 2 
replacements: the PEP-TALK Trial 3 
Alexander Ooms* 1 alexander.ooms@csm.ox.ac.uk 4 
Susan J Dutton1 susan.dutton@csm.ox.ac.uk 5 
Scott Parsons1,2 scott.parsons@ndorms.ox.ac.uk 6 
Beth Fordham1,2 beth.fordham@ndorms.ox.ac.uk 7 
Caroline Hing3 caroline.hing@stgeorges.nhs.uk 8 
Sarah Lamb4 S.E.Lamb@exeter.ac.uk 9 
Toby Smith2,5 toby.smith@ndorms.ox.ac.uk 10 
1. Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, Nuffield Department of 11 
Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK 12 
2. Centre for Rehabilitation Research in Oxford, Nuffield Department of Orthopaedics, Rheumatology 13 
and Musculoskeletal Sciences, University of Oxford, Oxford, UK 14 
3. University of London St George's Molecular and Clinical Sciences Research Institute, London, UK 15 
4. College of Medicine and Health Sciences, University of Exeter, Exeter, Devon, UK 16 
5. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK 17 
*Corresponding author 18 
Address for correspondence: Alexander Ooms 19 
    Oxford Clinical Trials Research Unit 20 
    Botnar Research Centre 21 
    Windmill Road 22 
2 
 
    Oxford 23 
    OX3 7LD 24 




Background:  Total hip (THR) and total knee replacements (TKR) are two highly successful orthopaedic 27 
procedures that reduce pain for people with osteoarthritis. Previous evidence suggests that physical 28 
activity, at best, remains the same pre- to post-operatively, and in some instances declines. The PEP-29 
TALK trial evaluates the effects of a group-based, behaviour change intervention on physical activity 30 
following a THR or TKR.  31 
Methods: PEP-TALK is an open, phase III, pragmatic, multi-centre, parallel, two-arm, two-way 32 
superiority randomised controlled trial investigating the effectiveness of usual care plus a behaviour 33 
change therapy compared with usual care alone following primary THR or TKR. The primary outcome 34 
is the UCLA Activity Score at 12 months post-randomisation which will be analysed using a linear mixed 35 
effects model. Secondary outcomes measured at six months and 12 months after randomisation 36 
include the UCLA Activity Score, Lower Extremity Functional Scale, Oxford Hip/Knee Score, Numerical 37 
Rating Scale for Pain, Generalised Self-Efficacy Scale, Tampa Scale for Kinesiophobia, Hospital Anxiety 38 
and Depression Scale, EuroQoL EQ-5D-5L index and EQ-VAS and complications or adverse events. Full 39 
details of the planned analysis approaches for the primary and secondary outcomes, as well as the 40 
planned sensitivity analyses to be undertaken due to the COVID-19 pandemic are described here. The 41 
PEP-TALK study protocol has been published previously. 42 
Discussion: This paper provides details of the planned statistical analyses for the PEP-TALK trial. This 43 
is aimed to reduce the risk of outcome reporting bias and enhance transparency in reporting.  44 
Trial Registration: International Standard Randomised Controlled Trials database, ISRCTN Number: 45 
29770908. 46 
KEYWORDS 47 




This analysis strategy adheres to the Statistical Analysis Plan Guidelines1. 50 
Total Hip (THR) and Total Knee Replacements (TKR) are two highly successful orthopaedic procedures 51 
which reduce pain for people with osteoarthritis2,3. Over 230,000 THR and TKRs were performed in 52 
the UK in 20192. Approximately 90% of patients are satisfied following THR and TKR3 with significant 53 
improvements in pain and physical function after three to 12 months3,4. However, medical co-54 
morbidities are common in this population. These include hypertension (56%)5, cardiovascular disease 55 
(20%)6, diabetes (16%)6 and multi-joint pain (57%)5. Twenty-seven percent of people who undergo 56 
joint replacement have three to four comorbidities6. Medical comorbidities such as these have a 57 
significant negative impact on both health-related quality of life and societal burden7,8. 58 
Historically, it has been assumed that people are more active following THR or TKR through the 59 
amelioration of their joint pain9. However, previous evidence has indicated that physical activity, at 60 
best, remains the same from pre- to post-operatively, and in some instances declines9. There does not 61 
appear to be a difference in physical activity trajectories between those following THR or TKR9,10. The 62 
reasons for reduced participation may differ between the groups10 with TKR more often associated 63 
with increased pain in the initial 12 post-operative months compared to THR3,4, whereas those with 64 
THR may have greater fear avoidance through the risks of joint implant dislocation3,4.   65 
Subsequent analyses from large USA and UK datasets have supported this finding, re-enforcing the 66 
notion that physical activity is lower after THR and TKR compared to age- and gender-matched cohorts 67 
who had not undergone joint replacement10. Given that physical activity can significantly reduce 68 
symptoms associated with common comorbidities11, this population’s physical inactivity has a 69 
detrimental effect on their health. Participating in regular physical activity can decrease the risk of 70 
cardiovascular disease by 52%12, diabetes by 65%13, some cancers by 40%14, reduces all-cause 71 
mortality by 33% and cardiovascular mortality by 35%15. Accordingly, supporting people to be more 72 
physically active can improve both patient’s health and decrease the economic burden these diseases 73 
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place on the NHS. To date, no interventions aimed to increase physical activity following joint 74 
replacement surgery have been robustly tested. To address this, the PEP-TALK trial was undertaken. 75 
METHODS 76 
Trial Design 77 
The trial is an open, phase III, pragmatic, parallel, two-arm, two-way superiority randomised 78 
controlled trial (RCT) on individuals investigating the effectiveness of usual care plus a group exercise 79 
and behaviour-change intervention versus usual care alone to increase physical activity following 80 
primary THR or TKR. Neither participants nor physiotherapists can be blinded to the treatment 81 
allocation. Primary comparison is assessed at 12 months post-randomisation with data being collected 82 
at baseline (pre-operatively), six months and 12 months post-randomisation. 83 
Participants will be screened for inclusion in the trial pre-operatively, consented pre-operatively and 84 
eligibility confirmed post-operatively. They will then be randomised prior to hospital discharge and 85 
notified of their group allocation to facilitate the organisation of their rehabilitation. Initially, 86 
participants were randomised to the two groups 1:1 using minimisation by trial centre, type of joint 87 
replacement (THR or TKR), and Charlson co-morbidity index (1-3 or ≥4). The minimisation algorithm 88 
will have a probabilistic element of 0.8 included to ensure unpredictability of treatment assignment. 89 
After 75 randomisations, the random allocation ratio was changed to 2:1 (Experimental Intervention: 90 
Usual Care). This change was made to ensure more participants were randomised to the experimental 91 
intervention group. The intervention is group-based and is designed to have three or more 92 
participants per group session. Based on evidence from early recruiting sites, there was difficulty to 93 
consistently fill sessions under a 1:1 allocation ratio. Therefore this change was deemed important to 94 
facilitate larger groups. This change was implemented by the Trial Management Group and approved 95 
by the Data Safety Monitoring Committee, Sponsor and Research Ethics Committee.  96 
Those randomised to usual care (the comparator) will receive six, 30-minute group-based exercise 97 
sessions. Those randomised to the experimental intervention will receive six group-based behaviour 98 
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change intervention sessions (30-minute duration) immediately followed by the control intervention 99 
of 30 minutes of group-based exercise and three follow-up telephone calls up to six weeks after 100 
completing the group sessions. Both group’s physiotherapy will commence within the initial four 101 
weeks post-randomisation and continue weekly for six weeks.  Further details of the trial design and 102 
procedures, including full eligibility criteria and trial interventions are found in the PEP-TALK trial 103 
protocol16. 104 
Outcomes 105 
Primary outcome  106 
The primary outcome measure is the UCLA Activity Score 12 months post-randomisation. The UCLA 107 
Scale is a reliable and valid self-reported tool to assess physical activity17, 18 that assesses global activity 108 
levels with a grading system of 1 to 10 where 1 equates to “wholly inactive, dependant on others and 109 
cannot leave residence” and 10 refers to “regularly participates in impact sports”. 110 
Secondary outcomes  111 
The secondary outcome measures, self-reported with partial answers being coded as missing and 112 
collected at baseline (except complications), six and 12 months post-randomisation unless otherwise 113 
stated, are as follows: 114 
• Functional outcome: Lower Extremity Functional Scale (LEFS)19: A questionnaire containing 20 115 
questions scored using a scale 0-80 with a higher score representing a higher functional level.  116 
• Disease specific function: Oxford Hip Score/Oxford Knee Score (OHS/OKS)20,21. A 12-item 117 
disease-specific questionnaire, scores range from 0 to 48 where 48 indicates high joint 118 
function. Murray et al22 recommends to impute the mean value representing all other items 119 
to fill in two or fewer missing items. 120 
• Perceived level of pain: Numerical Rating Scale (NRS) for Pain. An 11-point scale where 121 
participants mark their perceived pain between 0 representing ‘no pain’ to 10 representing 122 
the ‘worst possible pain’.  123 
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• Self-efficacy: Generalized Self-Efficacy Scale (GSES) 23. A 10-item scale with scores ranging from 124 
10 to 40, higher scores representing a high level of self-efficacy.  125 
• Fear avoidance: Tampa Scale for Kinesiophobia24. A 17-item self-completed questionnaire 126 
with scores from 17 to 68 where the higher scores indicate an increasing degree of 127 
kinesiophobia.  128 
• Psychological distress: Hospital Anxiety and Depression Scale (HADS) 25. This scale consists of 129 
14-items divided into two 7-item subscales: Anxiety and Depression. The total score is out of 130 
42, (21 per subscale), higher scores indicate greater levels of anxiety/depression or global 131 
psychological distress.  132 
• Health related quality of life: Euroqol EQ-5D-5L26. A patient reported health related quality of 133 
life questionnaire consisting of two parts. First, five domains related to daily activities with a 134 
5-level answer possibility are measured26,27, which will be converted into multi-attribute utility 135 
scores using established algorithm28. To calculate EQ-5D-5L Index scores the Crosswalk Index 136 
Value Calculator will be used to map the 5L descriptive system data onto the 3L dataset using 137 
the mapping function developed by van Hout et al27 as, at the time of writing this statistical 138 
analysis plan, there is still debate about the appropriate value set for the 5L. Secondly, the 139 
Euroqol VAS (EQ-VAS) is a 0 to 100 visual analogue score from the worse (0) to best health 140 
imaginable (100). Any participant who dies will have their EQ-5D-5L Index imputed as a score 141 
of zero for all time points after death, their EQ-VAS scores will be missing data for those time 142 
points.  143 
• Complications and adverse events will be collected throughout the trial.  144 
Sample size  145 
250 participants (125 per arm) are required to detect a standardised effect size of 0.4 with 80% power 146 
and 5% (2-sided) significance, allowing for 20% loss to follow-up. These calculations are based on the 147 
primary outcome at 12 months post-randomisation, assuming a baseline standard deviation of 2.529 148 
and a between-group difference of one. Our target standardised effect size is derived from the UCLA 149 
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Activity Score’s minimal clinically important difference of 0.9229. The sample size was increased to 260 150 
to account for the change in allocation ratio, maintaining the same power and type I error rate.  151 
Effect of COVID-19 pandemic 152 
The COVID-19 pandemic impacted on the conduct of the PEP-TALK trial. All elective surgeries, 153 
including THRs and TKRs, were cancelled as part of the UK national lockdown (23rd March 2020) and 154 
group-based physiotherapy classes within the hospital outpatient setting (a mechanism the trial relies 155 
on for both treatment groups) was stopped indefinitely.  156 
A direct consequence of the cancellation of THRs and TKRs was that the trial was no longer able to 157 
randomise eligible and consented participants and was forced to close recruitment prematurely (230 158 
final randomisations of the minimum sample size of 260).  159 
As the trial had been open to recruitment for less than 12 months by March 2020, none of the 160 
randomised participants reached the full 12-month follow-up without being affected by the COVID-19 161 
lockdown. This is particularly noteworthy in this instance as participants are likely to be in a 162 
demographic more medically vulnerable to the pandemic and all outcomes are assessed through 163 
Patient Reported Outcome Measures (PROMs). It is hypothesised the lockdown will be a confounder 164 
whilst assessing these outcomes, particularly those pertaining to more psychological aspects (e.g. the 165 
GSES) which may have been impacted by COVID-19 social measures on behaviour. However, as the 166 
trial is randomised, this effect should be the same across both treatment groups and therefore should 167 
not affect the overall treatment effect estimate.  168 
An indirect consequence of the pandemic on the trial is that it is possible, in a ‘post-COVID-19 world’, 169 
that what is considered “usual care” will be different to how that was perceived at the time of the 170 
trial’s conception (2016-2017). This has a potential effect on the generalisability of the results. The 171 
trial is pragmatic by nature and every effort has been made to follow-up participants to ascertain what 172 
intervention they actually received. Through reporting this information, it is hoped this trial will give 173 
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a non-conclusive indication of what usual care was during this change in practice as a result of the 174 
COVID-19 pandemic and the effectiveness of it.  175 
Due to the effects of the pandemic, analysis and data exploration unforeseen when writing the 176 
protocol have been included in this analysis plan. These additions, found in the relevant section of this 177 
paper, will assess the effect of the pandemic on the trial and provide insights on future physiotherapy 178 
service configuration. 179 
Note: The terms “COVID-19 status” and “pre-COVID-19/COVID-19” groups used within this paper refer 180 
to the definitions outlined in the ‘Definition of analysis populations’ section. This does not refer to 181 
participants who tested positive for COVID-19; testing information has not been collected as part of 182 
this trial.  183 
Statistical analysis 184 
General analysis principles  185 
There is one planned final analysis, which will occur 12 months after the final participant’s 186 
randomisation, allowing for appropriate time for the data to be collected, cleaned and prepared for 187 
final analysis.  There is no multiple testing as only a single primary outcome is considered.  Significance 188 
levels used will be 0.05 and 95% confidence intervals will be reported. Any analyses not pre-specified 189 
will be exploratory in nature and a significance level of 0.01 will be used to declare statistical 190 
significance and 99% confidence intervals will be presented. No formal interim analysis or predefined 191 
early stopping rules are planned for this trial. 192 
Definition of analysis populations 193 
• Intention-to-treat: inclusion of all available randomised participants who will be analysed in 194 
the groups to which they were randomly allocated irrespective of non-compliance. If a 195 
participant has observed data on any of the follow-up time points, they will be included in the 196 
analysis.  197 
10 
 
• Per protocol: eligible participants who received the treatment they were randomised to with 198 
data on the primary outcome at 12 months. Participants who had major protocol 199 
violations/deviation (e.g. not have received the treatment they were allocated to) will be 200 
excluded from this population. 201 
• Strict Compliers: participants who fall under the Strict Compliance definition outlined in the 202 
Compliance section. 203 
• Compliers: participants who fall under the Compliance definition outlined in the Compliance 204 
sectionError! Reference source not found.. 205 
• Attenders: participants who fall under the Attendance definition outlined in the Compliance 206 
section. 207 
• Pre- COVID-19: participants who completed their intervention before national UK lockdown 208 
(23rd March 2020) and had no disruption to their planned treatment. 209 
• COVID-19: participants who did not receive any intervention before 23rd March 2020 or had 210 
their intervention delivery disrupted by the UK lockdown. 211 
Descriptive analysis 212 
The flow of participants through each stage of the trial, including the number of individuals screened, 213 
eligible, randomised to each group, receiving allocated treatment, and included in the primary analysis 214 
will be summarised using a CONSORT flow chart (Figure 1). Reasons for ineligibility, loss to follow-up 215 
and exclusion from the primary analysis will be summarised. Participant follow-up data will be 216 
presented by randomised group as well as COVID-19 status (pre-COVID-19/COVID-19 as in the 217 
‘Definition of analysis populations’ section). 218 
Baseline characteristics will be reported by treatment group, including the minimisation factors and 219 
important prognostic, demographic and clinical covariates. Numbers (with percentages) for binary and 220 
categorical variables and means (and standard deviations), or medians (with lower and upper quartiles) 221 
for continuous variables will be presented, there will be no tests of statistical significance nor 222 
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confidence intervals for differences between randomised groups on any baseline variable. Baseline 223 
characteristics will also be reported by COVID-19 status in order to explore difference in demographics 224 
between these groups. 225 
It is likely that some data may not be available due to voluntary withdrawal of participants, lack of 226 
completion of individual data items or general loss to follow-up. The number (with percentage) of 227 
withdrawals from the trial and the numbers lost to follow-up for the primary outcome together with 228 
the associated reasons (where possible) will be reported by treatment group. Any deaths (and their 229 
causes) will be reported separately.  230 
Compliance 231 
Deviations from intended treatment (non-adherence to the protocol) will be summarised for the 232 
randomised groups; these will include non-compliance and withdrawal of consent. Details of 233 
compliance and what intervention was actually received will be reported by treatment group and also 234 
separately by COVID-19 status. Three levels of compliance: Strict Compliance, Compliance and 235 
Attendance have been defined as follows: 236 
Strict Compliance (as defined in the original Protocol16): 237 
Usual Care group: 238 
• Attends at least four out of six physiotherapy sessions 239 
Experimental Intervention group: 240 
• Attends at least four out of six group intervention sessions with a minimum of three 241 
participants per session 242 
• Receives two out of three follow-up telephone calls 243 
Compliance: 244 
Usual Care group: 245 
• Attends at least four out of six physiotherapy sessions 246 
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Experimental Intervention group: 247 
• Attends at least four out of six group intervention sessions with a minimum of three 248 
participants per session 249 
Attendance: 250 
Usual Care group: 251 
• Attends at least one out of six physiotherapy sessions 252 
Experimental Intervention group: 253 
• Attends at least four out of six group intervention sessions. 254 
Other indicators of compliance to the rehabilitation exercises (i.e. data collected from Exercise Diaries) 255 
may be summarised by treatment group in tabular or graphical form. The effect of changing 256 
randomisation ratio from 1:1 to 2:1 after 75 randomisations on levels of compliance will also be 257 
explored. 258 
 259 
Analysis of the primary outcome 260 
The primary outcome measure, the role of usual care versus usual care plus the experimental 261 
intervention upon the UCLA Activity Score at 12 months post-randomisation, will be modelled using a 262 
mixed effects model. This model will account for person within centre random effects, and Charlson 263 
Comorbidity Index score and baseline UCLA Activity Score (as continuous outcomes), type of operation 264 
the patient is undergoing (THR or TKR), time (six or 12 months) and treatment as fixed effects. 265 
Treatment by time point interactions will also be included in the model to allow time specific 266 
treatment effects to be calculated. This model uses all available data at each time point. Comparison 267 
will be performed on an intention-to-treat basis and results presented as comparative summary 268 
statistics (i.e. difference in means) with 95% confidence intervals. 269 
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The appropriateness of the assumption of approximate normality of the residuals of this model will 270 
be assessed graphically. If the residuals are not normally distributed, the outcome data will be log-271 
transformed to gain normality and geometric means with 95% confidence intervals will be reported. 272 
If data is not normally distributed after log-transformation, the non-parametric Mann-Whitney test 273 
will be used with no adjustment for baseline or stratification factors, and the difference in medians 274 
with 95% confidence intervals will be reported. 275 
Supporting Analyses of the Primary Analysis 276 
An area under the curve (AUC) analysis will be performed for the UCLA Activity Score. Estimates will 277 
come from the same mixed model used in the analysis of the primary outcome except including 278 
baseline UCLA Activity Score in the “time” fixed effect allowing time point specific treatment effects 279 
to be calculated for baseline, six months and 12 months. These estimates will be used to calculate the 280 
AUC. Using the estimates from the mixed-effects model rather than raw, unadjusted estimates results 281 
in less bias estimates of the AUC when missing data are present30.  282 
Complier average causal effect (CACE) analyses will be performed to find estimates for the causal 283 
effect of actually receiving the treatment and the overall treatment effect (including non-compliers) 284 
through intention to treat analysis. The definitions of Strict Compliance, Compliance and Attendance 285 
will be used to perform three CACE analyses.  286 
A supporting analysis of the primary outcome will use a three-level model with participant within 287 
predominant treating physiotherapist within centre to examine the potential physiotherapist (random) 288 
effects. This model will formally incorporate terms that allow for possible heterogeneity in responses 289 
for participants due to the recruiting centre and the physiotherapist. The model will include the same 290 
fixed effects used in the primary analysis model as well as treatment by time point interactions. 291 
 An additional supporting analysis of the primary outcome using a reduced version of the primary 292 
analysis model, only using person as a random effect, will be performed. This model is pertinent as 293 
Usual Care should be homogenous across the recruiting centres in a pragmatic trial so using a simpler 294 
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model may yield a better-fit model. Model fit compared to the primary analysis model will be assessed 295 
using Information Criteria. 296 
Analysis of the secondary outcomes 297 
The continuous secondary outcomes: to compare functional outcomes, disease-specific function, 298 
perceived level of pain, self-efficacy, fear avoidance, psychological distress and health-related quality 299 
of life between groups are assessed through the corresponding PROMs measured at baseline, six 300 
months and 12 months post randomisation. Mixed effects models, as used in the primary analysis, will 301 
be used to assess these outcomes. These models will account for person within centre random effects, 302 
and Charlson Comorbidity Index score and the relevant baseline PROM score (as continuous 303 
outcomes), operation type, time (six or 12 months) and treatment as fixed effects. Treatment by time 304 
point interactions will also be included in the model to allow time specific treatment effects to be 305 
calculated. 306 
There is expected to be a low number of complications/Serious Adverse Events (SAEs) in this trial. Any 307 
adverse events (AEs) occurring whilst a participant is continuing in the study, until completion of the 308 
final study visit will be recorded. All AEs will be reported and tabulated by grade and treatment group 309 
– similar reporting will be done with SAEs. The number of SAEs and number participants reporting one 310 
or more SAEs will be reported by treatment group. If there is large enough number of events for a 311 
comparison to be appropriate, then the complications in each group will be pooled and the “Total 312 
Complications” analysed by calculating the odds ratio and 95% confidence interval using logistic 313 
regression adjusting for minimisation factors (recruiting centre, Charlson Comorbidity Index (as a 314 
continuous value), and type of operation) and treatment.  315 
Sensitivity analyses 316 
Sensitivity analysis will assess the internal validity of the trial results by performing a per-protocol 317 
analysis on all participants who fall under the per-protocol definition as per the ‘Definition of analysis 318 
populations’ section. 319 
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Missing data 320 
Missing data analysis will be performed on the primary outcome only. The primary analysis multi-level 321 
model using repeated measures is relatively robust to missing data under the missing at random (MAR) 322 
assumption31. 323 
Analysis will be performed on an intention-to-treat basis. The number and percentage of participants 324 
in the missing category will be presented, as well as reasons for missingness if known. Missing data 325 
will be reported and summarised by treatment group. The distribution of missing data will be explored 326 
to assess the assumption of data being missing at random under which the principal analyses will be 327 
conducted. Varying scores of the UCLA Activity Score (e.g. 30th, 40th, 50th, 60th, 70th quantiles) will be 328 
imputed where data is missing and these “complete” datasets will be reanalysed, using the same 329 
model used in the primary analysis and the results presented in graphical form. This analysis will be 330 
undertaken if there is more than 5% missing data for the primary outcome at 12 months. 331 
If there is evidence that there is a departure from the MAR assumption, a search for factors not 332 
included in the primary analysis model that explain missingness will be performed and if variables are 333 
found, multiple-imputation using chained equations32 will be utilised, using the primary analysis model 334 
but including these variables to assess the sensitivity of the findings to missing data. If no variables are 335 
identified, multiple-imputation will not be performed. 336 
Pre-specified subgroup analysis 337 
All subgroup analyses will be on the primary outcome only. Subgroup analyses of the two clinical 338 
stratifying variables (type of operation and (THR or TKR), Charlson Comorbidity Index Score (1-3 or ≥4)) 339 
are planned. A subgroup analysis of COVID-19 status will also be performed. These will use an 340 
extended primary analysis model including an interaction term between treatment and each 341 
stratifying variable/COVID-19 status to define the subgroups. Subgroup analyses will be labelled as 342 
exploratory and results from will be interpreted with due caution; in line with recommendations for 343 
subgroup analysis made elsewhere33. The results will be presented in a forest plot.  344 
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Additional analysis 345 
A mediation analysis will be carried out. A priori mediation analysis mediators will include self-efficacy, 346 
fear avoidance, pain and psychological distress to compare the mediation pathways presented in the 347 
BeST intervention34 to the PEP-TALK intervention. 348 
An additional analysis will be performed to assess the effect of COVID-19 on activity at 12 months 349 
post-randomisation. The model used for the primary analysis will be extended to include COVID-19 350 
status (as a fixed effect) and a COVID-19 status by time point interaction. The adjusted mean 351 
difference of COVID-19 status will be reported with supporting 95% confidence intervals. It should be 352 
noted that formally investigating COVID-19 status’ effect on activity is outside the scope of the original 353 
trial design so results from this analysis are hypothesis generating and exploratory.  354 
Descriptive statistics on secondary outcomes of: GSES, the Tampa Scale for Kinesiophobia, HADS, EQ-355 
5D-5L Index, EQ-VAS and NRS for pain may be produced to further assess the impact of COVID-19. No 356 
formal analysis to examine the relationship between COVID-19 status and secondary outcomes will 357 
be performed.   358 
Statistical packages 359 
All analysis will be carried out using STATA35 or R36 statistical software. The package and version 360 
number used for analysis will be recorded and reported.  361 
DISCUSSION 362 
This paper provides details of the planned statistical analyses for the PEP-TALK trial to reduce the risks 363 
of reporting bias37 and includes pre-specified analyses planned to explore the effect of COVID-19. Any 364 
changes or deviations from the analysis outlined in this paper will be described and justified fully in 365 
the final report. 366 
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TRIAL STATUS 367 
The first participant was randomised into the study on the 12th of April 2019, final randomisation 368 
occurred on the 27th of March 2020. Randomisations were stopped due to COVID-19, 44 potential 369 
participants had consented and were awaiting surgery prior to randomisation when the trial closed. 370 
In total 230 participants, from eight participating centres, were randomised. Follow-up is currently 371 
ongoing and is expected to finish in April/May 2021 with final data lock occurring in Summer 2021. All 372 
analyses being conducted thereafter.  373 
LIST OF ABBREVIATIONS 374 
AE  Adverse event 375 
AUC   Area under the curve 376 
CACE  Complier average causal effect 377 
GSES  Generalized Self-Efficacy Scale 378 
HADS  Hospital Anxiety and Depression Scale 379 
LEFS  Lower Extremity Functional Scale 380 
MAR   Missing at Random 381 
NRS  Numeric Rating Scale 382 
OHS   Oxford Hip Score 383 
OKS  Oxford Knee Score 384 
PROM  Patient Reported Outcome Measure 385 
SAE  Serious Adverse Event 386 
THR  Total Hip Replacement 387 
TKR  Total Knee Replacement 388 
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UCLA  University of California, Los Angeles 389 
VAS  Visual Analogue Scale 390 
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